Piattaforma di telemedicina altamente redditizia e in forte crescita che serve il mercato tedesco della



PRINTED ON: *October 30, 2026, 9:54 PM (EST)* **PUBLISHED ON:** *March 9, 2026, 8:33 AM (EST)* **UPDATED ON:** *October 30, 2026, 8:54 PM (EST)*

MERGERSCORP

Piattaforma di telemedicina altamente redditizia e in forte crescita che serve il mercato tedesco della cannabis terapeutica

Un'opportunità unica per acquisire una piattaforma di telemedicina e prescrizione digitale in rapida espansione, conforme al GDPR e operante in ambito transfrontaliero nell'UE. L'azienda mette in contatto oltre 20.000 pazienti con medici e farmacie autorizzate in Germania.

Licenza/e posseduta/e

Opera nell'ambito della telemedicina transfrontaliera dell'UE (medici abilitati in Germania e Polonia). Piattaforma conforme al GDPR. Non è richiesta una licenza per la manipolazione diretta della cannabis.

Dettagli dell'annuncio

- L'azienda cipriota gestisce una piattaforma di telemedicina completamente digitale, che consente consulti a distanza e prescrizioni digitali
- Lanciata nel 2024, la piattaforma ha servito circa 20.000 pazienti ed elaborato oltre 6.500 prescrizioni al mese.
- Si è concentrata sull'ottimizzazione profonda dei processi per garantire la scalabilità prima di lanciare campagne di marketing mirate, tra cui la pubblicità su Facebook e il marketing di affiliazione, e continua a implementare nuove funzionalità per migliorare l'esperienza degli utenti.
- Un'attività redditizia con margini superiori al 60%, un fatturato attuale di circa 140.000 euro al mese e una previsione di 1,5 milioni di euro entro la fine dell'anno, con una crescita annuale del 20%.
- Il reddito è generato dalle prenotazioni di appuntamenti per i pazienti, dai servizi di marketing per le farmacie, dalle partnership con i principali produttori e dalle offerte di prodotti white-label.
- Opera in modo efficiente con circa 12 dipendenti/freelance, sfruttando gli specialisti freelance del front-end e del back-end.
- I flussi di lavoro automatizzati riducono i tempi di consultazione dei medici del 90% e la piattaforma supporta funzionalità white-label per una rapida espansione B2B.

TARGET PRICE
$ 9,000,000

GROSS REVENUE
$ 1,680,000

EBITDA
$ 1,008,000

BUSINESS TYPE
Aziende del settore sanitario

COUNTRY
Cipro

BUSINESS ID
L#20261003

MERGERSCORP M&A INTERNATIONAL IS A GLOBAL BRAND OPERATED BY MERGERSUS INC.A US CORPORATION WITH REGISTERED OFFICE AT 40TH WALL STREET, SUITE #2725, NEW YORK, NEW YORK 10005, UNITED STATES OF AMERICA.

- La crescita annua prevista del 15-20% è guidata dalla crescente domanda dei pazienti e dalla recente liberalizzazione del mercato tedesco della cannabis.

- Cerca di vendere completamente e include l'attività in corso, la proprietà intellettuale, il marchio, il database dei pazienti e la base di codice del software.

MERGERSCORP M&A INTERNATIONAL IS A GLOBAL BRAND OPERATED BY MERGERSUS INC.A US CORPORATION WITH REGISTERED OFFICE AT 40TH WALL STREET, SUITE #2725, NEW YORK, NEW YORK 10005, UNITED STATES OF AMERICA.

The information contained herein does not constitute an offer to sell or a solicitation of an offer or a recommendation to purchase securities under the securities laws of any jurisdiction, including the United States Securities Act of 1933, as amended, or any US state securities laws, or a solicitation to enter into any other transaction

The projected financial information contained in the Memorandum is based on judgmental estimates and assumptions made by the management of the target Company, about circumstances and events that have not yet taken place. Accordingly, there can be no assurance that the projected results will be attained. In particular, but without prejudice to the generality of the foregoing, no representation or warranty whatsoever is given in relation to the reasonableness or achievability of the projections contained in the Memorandum or in relation to the bases and assumptions underlying such projections and you must satisfy yourself in relation to the reasonableness, achievability and accuracy thereof.

By delivering this Memorandum, neither MergersUS Inc., nor its authorized agents are making any recommendations regarding the acquisition or strategies outlined herein. Interested parties shall exercise independent judgment in, and have sole responsibility for, determining whether an acquisition of the Company is suitable for them, and neither MergersUS Inc, nor its authorized agents have responsibility to, and will not, monitor the condition of interested parties to determine that an acquisition is or remains suitable for them. Among other things, suitability of an acquisition will depend upon an interested party's investment and business plans and financial situation.

This document is prepared for information purposes only. It is made available on the express understanding that it will be used for the sole purpose of assisting the recipients to decide whether they wish to proceed with a further investigation of the Proposed Transaction.

The recipients realize and agree that this document is not intended to form the basis of any investment decision or any other appraisal or decision regarding the Proposed Transaction, and does not constitute the basis for the contract which may be concluded in relation to the Proposed Transaction.

All information contained in this document may subsequently be updated and adjusted. MergersUS Inc. has not independently verified any of the information contained herein or on which this document is based. Neither the Company, nor its management or shareholders, nor MergersUS Inc. , nor any of their respective directors, partners, officers, employees or affiliates make any representation or warranty (express or implied) or accept or will accept any responsibility or liability regarding or in relation to the accuracy or completeness of the information contained in this document or any other written or oral information made available to any interested party or its advisers. Any liability in respect of any such information or any inaccuracy in or omission from the document is expressly disclaimed.

MERGERSCORP

© 2026 MergersCorp M&A International. All rights reserved.

© 2026 MergersCorp M&A International. MergersCorp™ M&A International is the collective brand name of independent affiliates of MergersCorp M&A International. For more details on the nature of our affiliation, please visit us on our website https://www.mergerscorp.com/disclaimer. MergersCorp M&A International is not a registered broker-dealer under the U.S. securities laws. MergersCorp M&A International does not offer or sell securities or provide investment advice or underwriting services. The articles or publications contained in this presentation are not intended to provide specific business or investment advice. The author or MergersCorp M&A International shall not be liable for any errors or omissions, or for any loss suffered by any person or organization acting or refraining from acting as a result of the content of this website. It is recommended that specific independent advice be sought before making any business or investment decision.

MERGERSCORP

WWW.MERGERSCORP.COM